Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia,

Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced that new findings from

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a lea

Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in

Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The la

Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) insider John Leite sold 4,015 shares of Veracyte sto

Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs t

Squarepoint Ops LLC decreased its holdings in Veracyte, Inc. (NASDAQ: VCYT) by 76.8% in the second q

Corient Private Wealth LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.9% in th

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to

Concurrent Investment Advisors LLC bought a new position in Veracyte, Inc. (NASDAQ: VCYT) during the

On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick am

UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target

GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likel

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a lea

Canada Pension Plan Investment Board bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the

Connor Clark and Lunn Investment Management Ltd. bought a new stake in Veracyte, Inc. (NASDAQ: VCYT)

Bamco Inc. NY purchased a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, acco

VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and ri

Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth fa

The health care sector's oversold stocks present buying opportunities for undervalued companies.

Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy

Bank of America Corp DE grew its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 14.7% during

Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth

Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and low

Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and l

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lower

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the

U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analys

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price targ

Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $582.000 million-$592.000 million to $590.00

Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and

Piper Sandler analyst David Westenberg initiates coverage on Veracyte (NASDAQ:VCYT) with a Overwe

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raise

Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price t

On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price targ

On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, In

Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the

Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised

Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $570.000 million-$582.000 million to $582.00

Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.52 per share which beat the analyst consens

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the